Production of sterols in oleaginous yeast and fungi
View Patent ↗The present invention provides methods for production of one or more sterol compounds. Further provided are methods and systems for producing engineered oleaginous yeast or fungi that are capable of production of one or more sterol compounds, and compositions which utilize the produced sterol compound(s).
1. An engineered Y. lipolytica strain that produces at least one sterol compound selected from the group consisting of: squalene, lanosterol, zymosterol, ergosterol or 7-dehydrocholesterol (provitamin D3), the strain containing one or more sterologenic modifications selected from the group consisting of:
a. decreased expression or activity of a Y. lipolytica GGPP synthase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
b. increased expression or activity of a truncated HMG CoA reductase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
c. increased expression or activity of an FPP synthase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
d. increased expression or activity of an IPP isomerase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
e increased expression or activity of an HMG-CoA synthase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
f. increased expression or activity of a mevalonate kinase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
g. increased expression or activity of a phosphomevalonate kinase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
h. increased expression or activity of a mevalonate pyrophosphate decarboxylate polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
i. increased expression or activity of a cytosolic malic enzyme polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
j. increased expression or activity of a malate dehydrogenase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
k. increased expression or activity of an AMP deaminase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
l. increased expression or activity of a glucose 6 phosphate dehydrogenase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
m. increased expression or activity of a malate dehydrogenase homolog 2 polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
n. increased expression or activity of a GND1-6-phosphogluconate dehydrogenase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
o. increased expression or activity of a isocitrate dehydrogenase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
p. increased expression or activity of a IDH2-isocitrate dehydrogenase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
q. increased expression or activity of a fructose 1,6 bisphosphatase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
r. increased expression or activity of a Erg10-acetoacetyl CoA thiolase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
s. increased expression or activity of a squalene synthase polypeptide; and combinations thereof compared to an otherwise comparable strain lacking the one or more sterologenic modification;
wherein the engineered strain can accumulate lipid to at least about 20% of its dry cell weight; and
wherein as a result of genetic engineering the engineered strain produces the at least one sterol compound to a level at least about 1% of its dry cell weight.
2. The engineered Y. lipolytica strain of claim 1 , wherein the one or more sterologenic modifications is selected from the group consisting of:
a. decreased expression or activity of a Y. lipolytica GGPP synthase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
b. increased expression or activity of a squalene synthase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification;
c. increased expression or activity of a truncated HMG CoA reductase polypeptide compared to an otherwise comparable strain lacking the one or more sterologenic modification; and combinations thereof.
3. The engineered Y. lipolytica strain of claim 1 , wherein the produced sterol compound accumulates to levels that are greater than at least about 1.0%, greater than at least about 2.5%, or greater than at least about 5% of the dry weight of the cells.
4. The engineered Y. lipolytica strain of claim 1 , wherein the sterol compound is squalene.
5. The engineered Y. lipolytica strain of claim 1 , wherein the sterol compound is lanosterol.
6. The engineered Y. lipolytica strain of claim 1 , wherein the sterol compound is zymosterol.
7. The engineered Y. lipolytica strain of claim 1 , wherein the sterol compound is ergosterol.
8. The engineered Y. lipolytica strain of claim 1 , wherein the sterol compound is 7-dehydrocholesterol.
9. The engineered Y. lipolytica strain of claim 1 , further comprising at least one, oleaginic modification,
wherein as a result of the at least one oleaginic modification, the strain produces the at least one sterol compound to a level at least about 1% of its dry cell weight.